Jonathan Berman

Jones Day (Washington DC)
Lawyer (Partner)

Jonathan Berman splits his practice between complex commercial litigation and advising on food and drug regulatory issues. Jonathan advises on topics spanning the breadth of the Food, Drug, and Cosmetic Act and other laws administered by the FDA. Jonathan’s litigation practice has emphasized class action and antitrust matters, and he argued one of the first litigated motions involving using "predictive coding" of electronic documents.


Linked authors

Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Washington DC)


103 Bulletin

Jonathan Berman, Rosanna McCalips, Julia McEvoy, Larissa Bergin The U.S. Congress implements a new law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities (Patient Right to Know Drug Prices Act)


New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar (...)

Send a message